NCT06281106

TYK2 Inhibition in Paradoxical Psoriasis

Tyrosine Kinase 2 (TYK2) Inhibition in Paradoxical Psoriasis A Randomized, Double-blind, Placebo-controlled Multi-center Study Evaluating the Effect of Deucravacitinib on Severity of Psoriasis in Patients With Paradoxical Psoriasis

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Prof Curdin Conrad · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Deucravacitinib	Daily drug intake for 4 weeks.

Timeline

• Start date: 2024-06-20
• Primary completion: 2025-03-20
• Completion: 2025-03-20
• First posted: 2024-02-28
• Last updated: 2025-04-02

Locations

1 site across 1 country: Switzerland